logo-loader
viewHikma Pharmaceuticals Plc

Hikma Pharmaceuticals posts loss after US write-down

Hikma has shed two-thirds of its value over the past year due to product setbacks and a profit warning in August

inhaler
Glaxo can breathe easier for a few more years

Hikma Pharmaceuticals PLC (LON:HIK) slumped into a loss as it wrote down the value of the West-Ward Columbus acquisition by more than US$1bn.

The move marked yet another disappointment for the generic drug manufacturer, which has shed two-thirds of its value over the past year due to product setbacks and a profit warning.

READ: Hikma Pharmaceuticals and Vectura hit by US regulatory setback

Earlier this week, an alternative to GlaxoSmithKline’s Advair asthma inhaler that was being developed with Vectura was rejected by the US Food and Drug Administration until at least 2020.

Losses in 2017 were US$738mln (US$210mln profit), with sales also lower at US$1.94bn.

Core profit fell 9% to US$328mln as operating margin fell to 19.9% from 21.5% reflecting lower profitability in the Generics and Injectables businesses.

Going forward, Hikma said Injectable division revenues will be flat in 2018, Generic sales will fall while Branded products will see mid-single digits growth.

Jordan–based Hikma added that cash generation had been a record over the year and the annual dividend rises to 34c from 33c.

West-Ward Columbus was acquired in 2016 for US$2.65bn.

Shares rose 8% to 940p as brokers said the core profit was well ahead of some of the gloomier forecasts beforehand, while after their heavy fall there was not much downside left.

-- adds share price--

Quick facts: Hikma Pharmaceuticals Plc

Price: 1911 GBX

AIM:HIK
Market: AIM
Market Cap: £4.63 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

11 minutes ago

2 min read